INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
11/03/2026
Voltar para busca
Dado oficial do USPTO
CELLSPRESSO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
12/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
24/07/2017
Data de registro
25/12/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/07/2025
Última transação
12/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
BERLIN, JUSTIN E
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Cell Therapy Limited
Representantes
Melanie Howard Loeb & Loeb LLP
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of diseased skintissueorgans and body parts in the nature of treatment for viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases; veterinary pharmaceutical preparations for the treatment of diseased skintissueorgans and body parts in the nature of treatment for viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases; pharmaceutical preparations and substances for the treatment of damaged skin and tissuetissue regenerative pharmaceutical preparations; cellular medicinesstem cells for medical or veterinary use; reagents for medical or veterinary use; clinical medical and veterinary reagents; medical and veterinary diagnostic reagents; reagents for medical and veterinary diagnosis and medical and veterinary diagnostic research; chemical reagents for testing aqueous solutions for medical and veterinary purposes; reagents for use in biological processing for medical and veterinary purposes; media for biological and bacteriological cultures for medical and veterinary use; non-aqueous solvents for use in tests for medical and veterinary purposes; aqueous solutions for use in tests for medical and veterinary purposes; non-aqueous culture media for medical and veterinary use; chemicals preparationsbuffer solutions for use in tests for medical and veterinary purposes; chemicalssurfactants for use in tests for medical and veterinary purposes
Classe 10
Medical and veterinary devicesinstruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skintissueorgans and body parts; disposable cartridges for medical and veterinary devicesinstruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skintissueorgans and body parts; portable medical and veterinary apparatusinstruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skintissueorgans and body parts; surgicalmedicalveterinary apparatusdevicesinstruments for use in implanting regenerative cells into humans and animals to treat damaged and diseased skintissueorgans and body parts; surgicalmedicalveterinary apparatusdevicesinstruments for use in cell therapy and regenerative medicine; medical and veterinary devicesapplicators to implant regenerative cells into humans and animals for the treatment of damaged and diseased skintissueorgans and body parts; sample preparation devices for medical diagnostic use; apparatus for the regeneration of stem cells for medical purposes; component parts and fittings for all of the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
C71T
CANCELLED SECTION 71
11/07/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
25/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/12/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
25/10/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/04/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/04/2019
FIMP
FINAL DISPOSITION PROCESSED
05/04/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/03/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
25/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2018
PUBO
PUBLISHED FOR OPPOSITION
09/10/2018
GPNX
NOTIFICATION PROCESSED BY IB
06/10/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/09/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
19/09/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/09/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/08/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
03/08/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/08/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
03/08/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/06/2018
RFNP
REFUSAL PROCESSED BY IB
16/02/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
26/01/2018
RFRR
REFUSAL PROCESSED BY MPU
26/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/01/2018
CNRT
NON-FINAL ACTION WRITTEN
18/01/2018
MAFR
APPLICATION FILING RECEIPT MAILED
30/12/2017
DOCK
ASSIGNED TO EXAMINER
26/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/12/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLSPRESSO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.